The dose-finding study concluded that administration of brentuximab vedotin produced a lasting objective response while promoting tumor regression in patients with CD30-positive relapsed or refractory HL and ALCL. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.